CEO – Ron Myers, J.D., M.S.

nexgeniacorpron myersRon Myers brings more than 20 years of biotech experience to his new role as CEO of Nexgenia, most recently as chief legal officer and VP of strategic transactions at the Institute for Systems Biology in Seattle, WA. Myers was also the Chief Business Officer at VLST Corp. and, prior to that, held executive positions at both Corixa Corp. and Pfizer.


CSO – Nicole Provost, Ph.D.

nexgeniacorpnexgeniacorpNicole Provost brings decades of expertise in biotechnology and biochemistry to the Nexgenia CSO role. Dr. Provost most recently served as VP of Product Development at Dendreon Corp., where for ten years she was responsible for the development of cellular cancer therapies, protein processes, and analytical methods, as well as GMP clinical manufacturing. Prior to Dendreon, Dr. Provost served as Director of Product Development at CellPro Inc., where for eight years she was responsible for the development of immune cell selection devices and reagents, protein processes, and analytical methods. Dr. Provost received her BA in Chemistry from Wellesley College, and her MS in Bioengineering and PhD in Biochemistry from the University of Washington.